

Consensus or Controversy? Documenting and Discussing Clinical Investigators' Practice Patterns in Myelofibrosis

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Prior to initiating treatment with fedratinib, which of the following nutritional elements should be evaluated, replenished and monitored?
 - a. Vitamin C
 - b. Folate
 - c. Thiamine
 - d. Iodine

2. Which of the following proteins is targeted by pelabresib?
 - a. ACVR1
 - b. JAK2
 - c. IRAK1
 - d. BET

3. Which of the following statements best describes the relationship between spleen volume and survival among patients who received ruxolitinib for myelofibrosis (MF) in the Phase III COMFORT-I and COMFORT-II trials?
 - a. No correlation was observed
 - b. Reduction in spleen volume correlated with longer survival
 - c. Reduction in spleen volume correlated with shorter survival

4. Fedratinib is FDA approved in which of the following settings?
 - a. Low-risk or intermediate-risk MF with platelet counts $\geq 50 \times 10^9/L$
 - b. High-risk MF with platelet counts $< 50 \times 10^9/L$
 - c. Intermediate-2 or high-risk MF with platelet counts $\geq 50 \times 10^9/L$

5. Which of the following outcomes best describes patient-reported quality of life (QoL) with pacritinib 200 mg twice a day for MF in the Phase III PERSIST-2 trial?
 - a. Most patients reported no change in QoL
 - b. Most patients reported minimally or much worse QoL
 - c. Most patients reported much or very much improved QoL